A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
About this episode
The episode discusses the role of antibody-drug conjugates in precision oncology and their impact on metastatic non-small cell lung cancer treatment.
Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell lung cancer (mNSCLC). Despite their growing impact, the mechanisms behind ADCs remain unclear for many clinicians and multidisciplinary care teams. At the same time, the expanding use of immuno-oncology (IO) therap...
More episodes of CEConversations
- Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
- Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN
- Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
- MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management
- Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies
- The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations
Explore listener stats, chart rankings, contacts and more on the CEConversations podcast page.